Artisan Partners Limited Partnership Adds $244M in ICON Public Limited Company ($ICLR)
Key Points
- Artisan Partners Limited Partnership changed its ICON Public Limited Company ($ICLR) stake by 20.44% last quarter, boosting to 8,278,945 shares worth $1.44 billion.
- $ICLR last traded around $173.71.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Artisan Partners Limited Partnership increased its position in ICON Public Limited Company ($ICLR) by 20.44% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,278,945 shares of ICON Public Limited Company after buying 1,404,968 shares during the quarter. Artisan Partners Limited Partnership's holdings in ICON Public Limited Company were worth $1.44 billion as of its most recent filing.
ICON Public Limited Company Stock Up 2.2%
Shares of ICON Public Limited Company ($ICLR) traded around $173.71 on Saturday, up 2.2% for the day.
ICON Public Limited Company Earnings
Analysts Set New Price Targets
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Get ICON Public Limited Company alerts
New 13F filings, insider trades, and analyst moves on $ICLR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.